Biotech News

PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen (PEPG)PepGenEarnings

– Positive FREEDOM2-DM1 10 mg/kg cohort results demonstrated highest reported splicing correction and improvements across multiple functional measures – – 12.5 mg/kg FREEDOM2-DM1 cohort fully enrolled, with participants having received up to three doses; results expected in 1H 2027 – – FREEDOM-OLE

Related news

PepGen

Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2...

Recent company news

Stock data

Close
3.93 USD
Market cap
100.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States